scholarly journals Complete sequence of the genes encoding the VH and VL regions of low- and high- affinity monoclonal lgM and lgA1 rheumatoid factors produced by CD5+ B cells from a rheumatoid arthritis patient

1991 ◽  
Vol 3 (9) ◽  
pp. 865-875 ◽  
Author(s):  
Nagaradona Harindranath ◽  
Inna S. Goldfarb ◽  
Hideyuki Ikematsu ◽  
Samuele E. Burastero ◽  
Ronald L. Wilder ◽  
...  
2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1061.1-1061
Author(s):  
G. Larid ◽  
M. Pancarte ◽  
G. Offer ◽  
C. Clavel ◽  
M. Martin ◽  
...  

Background:Rheumatoid arthritis (RA) is associated with HLA-DRB1 genes encoding the shared epitope (SE), a 5 amino acid motive. RA is usually preceded by the emergence of anti-citrullinated protein antibodies (ACPAs) detected by anti-CCP2 tests. Citrullin is a neutral amino acid resulting from post translational modification of arginin by Peptidyl Arginyl Deiminases (PADs). ACPAs recognize epitopes from citrullinated human fibrinogen (Fib-cit) and can be specifically detected by the AhFibA assay. Five peptides derived from Fib-cit together represent almost all of the epitopes recognized by patients with ACPA-positive RA: β60–74cit, α36–50cit, α621–635cit, α501–515cit and α171–185cit. As RA is a pleiomorphic disease, whose evolution is difficult to predict, the use of antibody fine specificity as a marker of clinical phenotypes has become a major challenge.Objectives:Our objective was to study whether clinical characteristics and HLA-DRB1 genetic background were associated with a specific reactivity against these epitopes.Methods:184 ACPA positive RA patients fulfilling the 2010 ACR/EULAR criteria were studied. Patients characteristics, including HLA-DRB1 genotype, were collected from their medical files. Anti-CCP2, AhFibA, Rheumatoid Factors (RF), and antibodies against the five major Fib-cit peptides were analyzed using ELISA assays.Results:Anti-CCP2 and AhFibA titres were strongly correlated (rs: 0.7037; p = 5.69x10-29, Pearson’s). Anti-α505-515cit antibodies were associated with HLA-DRB1*04:01 (OR = 5.52 [2.00 – 13.64]; p = 0.0003). High level anti-α505-515cit antibodies were significantly associated with rheumatoid nodules (OR = 2.71 [1.00 – 7.16], p= 0.044). Anti α501–515cit antibodies were associated with RF (OR=2.31 [1.10 – 4.78], p= 0.026).Conclusion:Immune complexes containing anti-α501–515cit antibodies and rheumatoid factors might be involved in the development of rheumatoid nodules on the HLA-DRB1*04:01 background. These findings highlight the role played by the HLA-DRB1*04:01 molecule and its rapid intracellular route into the lysosomes, enabling original antigen processing. Finally, purifying these epitope specific antibodies might be a new therapeutic opportunity for rheumatoid nodules.Disclosure of Interests:None declared


1988 ◽  
Vol 168 (6) ◽  
pp. 1979-1992 ◽  
Author(s):  
S E Burastero ◽  
P Casali ◽  
R L Wilder ◽  
A L Notkins

In patients with rheumatoid arthritis (RA), circulating CD5+ B lymphocytes, but not CD5- B lymphocytes, are increased in number and size, exist in an activated state, spontaneously proliferate, and secrete Ig that binds to the Fc fragment of IgG. By constructing continuous mAb-secreting cell lines from CD5+ B lymphocytes, the properties and dissociation constants (Kd) of these antibodies were determined. Two types of rheumatoid factors (RFs) with discrete reactivities were produced. The first type is polyreactive and binds with relatively low affinity (Kd, 10(-5) mol/liter) to the Fc fragment of IgG. These antibodies are similar to those produced by CD5+ B cells from healthy subjects. The second type of RF is monoreactive and binds with higher affinity (Kd, 10(-7) mol/liter) to the Fc fragment of IgG. These latter autoantibodies are produced by CD5+ B cells of RA patients, but not healthy subjects. Long-term longitudinal studies are needed to determine the role of these two types of RFs in the pathogenesis of RA.


BIO-PROTOCOL ◽  
2019 ◽  
Vol 9 (17) ◽  
Author(s):  
khaled Amara ◽  
Lena Israelsson ◽  
Ragnhild Stålesen ◽  
Peter Sahlström ◽  
Johanna Steen ◽  
...  

Author(s):  
K. M. Thompson ◽  
I. Randen ◽  
Ø. Førre ◽  
J. B. Natvig

Sign in / Sign up

Export Citation Format

Share Document